skip to content

Cyprotex

18:15 on 20/12/2016

Current Price 159.10p | Bid 0.00p | Ask 0.00p | Change 0.00%

Company Overview

Cyprotex plc was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe PK for in vivo PK prediction.

Stock Details

EPIC CRX
ISIN GB00BP25RZ14
Shares in Issue 22,468,340
Market cap £ 32.69m
Sector Pharmaceuticals & Biotechnology
Indices FTSE AIM All-Share Index

Financial Highlights Year Ended 31/12/2015

Turnover £15.61 million
Operating Profit £1.98 million
Dividend Yield 0.00
Dividend Per Share 0.00
Dividend Cover 0.00
P/E Ratio -5.02
» More Financials

Key Personnel

Anthony Baxter CEO
John Dootson CFO

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Price Summary

Mid Price ? 0.00p
Bid Price ? 0.00p
Ask Price ? 0.00p
Volume ? 0
Change Today 0.00p
% Change Today 0.00%
Open 0.00p
Previous Close 160.50p
Intraday High 0.00p
Intraday Low 0.00p
52 Week High 148.50p
52 Week Low 60.00p

Intra-Day Chart

More Charts »

Broker Consensus

The broker consensus chart is currently unavailable.

Client Area Access

» Secure Login

» Not registered yet?

Aberdeen Ediston

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.